Efficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy

• Published in: Archives de pédiatrie : organe officiel de la Société française de pédiatrie Vol. 26; no. 4; pp. 238 - 246
• Main Authors: Bocquet, A., Dupont, C., Chouraqui, J.-P., Darmaun, D., Feillet, F., Frelut, M.-L., Girardet, J.-P., Hankard, R., Lapillonne, A., Rozé, J.-C., Simeoni, U., Turck, D., Briend, A.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-05-2019; Elsevier
• Subjects: Cow's milk allergy; Extensively hydrolyzed cow's milk protein formula; Food and Nutrition; Growth; Human health and pathology; Hydrolyzed formulas; Hydrolyzed rice-protein formulas; Life Sciences; Extensively hydrolyzed cow's milk protein formula; Cow's milk allergy; Hydrolyzed formulas; Growth; Hydrolyzed rice-protein formulas
• ISSN: 0929-693X; 1769-664X
• DOI: 10.1016/j.arcped.2019.03.001

Foods for special medical purposes (FSMPs) with a protein fraction made of hydrolyzed rice protein (HRPs) have been on the market in Europe since the 2000s for the treatment of cow's milk protein allergy (CMPA). HRP formulas (HRPFs) are proposed as a plant-based alternative to cow's milk protein-based extensively hydrolyzed formulas (CMP-eHF) beside the soy protein formulas whose use in CMPA is controversial. HRPFs do not contain phytoestrogens and are derived from non-genetically modified rice. HRPFs are strictly plant-based apart from the addition of vitamin D3 (cholecalciferol). As the amino acid content of rice proteins differs from that of human milk proteins, the protein quality of these formulas is improved by supplementation with free lysine, threonine, and tryptophan. The consumption of HRPFs has risen: for example, in France HRPFs account for 4.9% in volume of all formulas for children aged 0–3 years. Several studies have shown the adequacy of HRPFs in treating CMPA. They ensure satisfactory growth from the 1st weeks of life for infants and toddlers, both in healthy children and in those with CMPA. HRPFs can be used to treat children with CMPA either straightaway or in second intention in cases of poor tolerance to CMP-eHF for organoleptic reasons or for lack of efficacy. In France, the cost of HRPFs is close to that of regular infant or follow-on formulas.